2015-2016 CBMTG ANNUAL REPORT 2015-2016 CBMTG ANNUAL REPORT CBMTG HEAD OFFICE 570 West 7th Avenue, Suite 400 Vancouver, BC V5Z 1B3 T: 604-874-4944 F: 604-874-4378 E: cbmtg@cbmtg.org W: www.cbmtg.org 1
2015-2016 CBMTG ANNUAL REPORT TABLE OF CONTENTS PRESIDENT S MESSAGE 4 ABOUT 5 Mission 5 Vision 5 Values 5 Philosophy 5 Organization Chart 5 Board 6 Committee and SIG leads 6 Head Office Staff 6 MEMBERSHIP STATISTICS 7 STRATEGIC PLAN 8 STRATEGIC ACHIEVEMENTS 9 PROGRAMS 10 Webinar 10 National Registry 11 GVHD 2015 14 Conference 2016 14 Themed Meetings 2017 15 Leadership 16 AWARDS 16 ASSOCIATION SPONSORS 17 AUDITED FINANCIAL STATEMENTS 19 3
PRESIDENT S MESSAGE Dear CBMTG Members, I am pleased to present the annual report of the Canadian Blood and Marrow Transplant Group for 2015/16. Over the past year our society has continued to grow in size and scope. At 384 members the CBMTG has the largest and most diverse membership ever. We have renewed our focus on our Special Interest Groups and have broadened our activities to include advocacy in the field of blood and marrow stem cell transplantation. In the past year the CBMTG has positioned itself to be the voice of professionals working in the field of blood and marrow stem cell transplantation. We led the response to the Melphalan shortage last year and worked closely with representatives of Health Canada to secure a new supply of this critical drug. In order to support this activity we have realized that we need to develop closer ties with the individual transplant programs and have established a BMT Directors Committee. We hope that this committee will enable us to advocate more effectively for resources for the care of BMT patients. We have also decided to engage more with Canadian BMT patients and their families. The inaugural Patient Symposium held after the Annual Meeting in Vancouver was an opportunity to hear from patients about what would have helped them going through transplant. Many indicated how hard it was for them to find information about living posttransplant written from the patient s perspective. They also expressed an interest in becoming more engaged in research and in knowledge translation. We will continue to support this group by creating a Patient and Family Special Interest Group within the CBMTG. In future we hope to include Patient Symposia in future meetings to build stronger relationships with these natural allies. Research remains a central focus of the CBMTG. The National Registry continues to grow and by the end of 2016 will receive data from 16 Canadian transplant centers located in all regions of the country and reflecting both pediatric and adult programs. The first publication from the registry was presented by Dr. K. Paulson at the BMT Tandem Meetings in Honolulu in March 2016. Work has already started on our next publication describing the state of HCT in Canada in the 21 st Century. Dr. K. Schultz has joined the Board of the CBMTG in the position of Director-at-Large, Research, and will be looking at infrastructure needs to foster interventional studies in HCT in Canada. Our educational programs remain strong and will expand further under the new leadership of Dr. K. Lepic, Directorat-Large, Education. We continue to see growth in the attendance at webinars. We will focus on developing leaders in BMT by hosting a leadership training program in Toronto in November. Rather than holding a large annual meeting next year we will host three themed meetings in 2017; themes will include Innovation (Calgary), Resilience (Winnipeg) and Before and After Care (St. John s) and meetings are open to CBMTG members from across the country. We will meet up again at our next Annual Meeting in Ottawa in the spring of 2018. CBMTG s goals in the upcoming year will be to continue to build the research infrastructure, encourage collaboration between programs to address clinical, regulatory and administrative challenges, and to further develop the association special interest groups. I wish to thank the CBMTG board of directors, committee chairs, members and staff who work towards the vision of CBMTG. I invite all members to be involved and participate with the association. Sincerely, Andrew Daly, MDCM, FRCPC President 4
2015-2016 CBMTG ANNUAL REPORT ABOUT The Canadian Blood and Marrow Transplant Group (CBMTG) is a member-led, national, multidisciplinary organization providing leadership and promoting excellence in patient care, research, and education in the field of blood and marrow transplant. Our Mission The Canadian Blood and Marrow Transplant Group is the voice of experts working in the field of blood and marrow transplant. Vision Canada will be the best place in the world to have a blood and marrow transplant. Values Excellence, innovation, integrity, collaboration and professionalism in care, education and research in blood and marrow transplant. Philosophy CBMTG believes that every patient has a right of equal access to the highest quality of life saving care that can be provided by blood and marrow transplant professionals in Canada. Organization Chart CBMTG BOARD OF DIRECTORS PRESIDENT, PRESIDENT ELECT, PAST PRESIDENT, SECRETARY, TREASURER, EXECUTIVE DIRECTOR (EX-OFFICIO), DIRECTOR-AT-LARGE RESEARCH, DIRECTOR-AT-LARGE EDUCATION CBMTG HEAD OFFICE Reports via the President RESEARCH COMMITTEES Reports via the Director-at- Large Research EDUCATION COMMITTEES Report via the Director-at-Large Education SPECIAL INTEREST GROUPS Report via the Secretary FINANCE COMMITTEE Reports via the Treasurer FUNDRAISING COMMITTEE Reports via the President National Registry Steering Committee Symposia Planning Committee Nursing Special Interest Group Clinical Trials Network Webinar Planning Committee Laboratory Special Interest Group Conference Planning Committee Pharmacy Special Interest Groups Small Budget Research Grants Committee Themed Meetings Planning Committee Pediatric BMT Patient and Family Special Interest Group BMT Directors Special Interest Group 5
Board President, Andrew Daly, MD President-Elect, Donna Wall, MD Past President, Christopher Bredeson, MD, MSc, FRCPC Treasurer, Raewyn Broady, MBChB, FRACP, FRCPA, FRCPC Secretary, Jennifer Wiernikowski, MN, NP-Adult, CON(C) Director-at-Large, Education Kylie Lepic, MD Director-at-Large, Research Kirk Schultz, MD, FCAHS Committee Leads National Registry Steering: Dr. Kristjan Paulson Clinical Trial Network: Dr. Kirk Schultz Small Budget Research Grants: Dr. David Szwajcer GVHD Symposium: Dr. Silvy Lachance Webinar Planning: Dr. Mohamed Elemary Finance Committee: Dr. Raewyn Broady Fundraising: Dr. Ronan Foley Education: Dr. Kylie Lepic SIG Leads Laboratory: Ms. Angela Hall Nursing: Ms. Jennifer Wiernikowski and Ms. Samantha Mayo Pediatrics: Dr. Donna Wall Pharmacy: Ms. Dawn Warketin Patient and Family: TBD Head Office Staff Ms. Ana Torres, Executive Director Ms. Kimberly Tan, Association Coordinator Ms. Jolie Ko, Association Administrator Mr. Paul Fogerty, Meeting Manager Ms. Samantha Wale, Association Coordinator (Maternity Leave) 6
2015-2016 CBMTG ANNUAL REPORT MEMBERSHIP STATISTICS HISTORY *As of July 2016 172 154 163 162 187 249 334 335 384* 2008 2009 2010 2011 2012 2013 2014 2015 2016 MEMBER TYPE NUMBER % BMT Director 26 7% Data Manager 7 2% Fellow 50 13% Lab 39 10% Nurse 73 19% Associate Director 11 3% Other* 41 11% Pharmacist 18 5% Physician 85 22% Professor/Assistant 19 5% Research Scientist 7 2% Unknown 8 2% 22% 5% 2% 5% 2% 2% 7% 13% 11% 10% 19% 3% *Other: Administrator, BMT Specialist/BMT Processing Lead, Chief Assistant, Clinical Associate, Clinical Research Coordinator, Coordinator, Development Specialist, Dietitian, Donor Search Coordinator, Executive Director, General Duty Technologist, Graduate Student, Manager, Physician Assistant, Program Manager, Provincial Leader of Hematology & BMT, Psychologist, Quality Assurance, Quality Manager, Research Assistant, Research Coordinator, Resident, Scientific Director, Senior Manager, Donation, TM and Stem Cell Supervisor, Trainee, Transplant Coordinator GEOGRAPHIC DISTRIBUTION Alberta 53 members 15% British Colombia 51 members 14% Manitoba 18 members 5% New Brunswick 9 members 3% Newfoundland 5 members 1% Nova Scotia 5 members 1% Ontario 129 members 36% PEI 2 members 1% Quebec 55 members 15% Saskatchewan 22 members 6% International 10 members 3% 14% 15% 6% 5% 36% 15% 3% International 1% 1% 3% 1% 7
STRATEGIC PLAN EDUCATION Providing high quality educational programmes that advance the practice of blood and marrow transplantation in Canada. RESEARCH Establish and organize an effective and sustainable research infrastructure for translational and clinical research. the CBMTG vision is: Canada will be the best place in the world to have a blood and marrow transplant. FINANCIAL CAPACITY To support, education, research and outreach initiatives through fundraising, partnerships and the establishment of a charitable organization. OUTREACH Increase the visibility and influence of CBMTG among members and the public. 8
2015-2016 CBMTG ANNUAL REPORT STRATEGIC ACHIEVEMENTS Education 2016 Annual Conference saw increased attendance and abstract submissions from the previous year We saw increased attendance to the CBMTG Webinars. We have a new webinar committee which is now led by Dr. Mohammed Elemary We recruited a new Director-at-Large Education, Dr. Kylie Lepic We changed the structure of the CBMTG Annual meeting for 2017; we will be holding three themed meetings in Calgary, Winnipeg and St. John s Our next National Meeting will be in 2018 in Ottawa Research The registry includes 80% capture of allogeneic transplants and around 60% capture of all autologous transplants in Canada We recruited a new Director-at-Large Research, Dr. Kirk Schultz Outreach CBMTG took on a leadership role to address the Melphalan shortage. We collaborated with the Canadian Association of Provincial Cancer Agencies when the matter arose in late 2015 We established a committee for BMT Directors to help advise on issues of outreach First ever patient symposium in 2016 Financial Capacity We have an active fundraising committee We secured our first donation to the charity We will be collaborating with the organizers of Holeigh Day. The proceeds of this baseball tournament will benefit CBMTG s research initiatives Our financial position is good. 9
PROGRAMS Webinar CBMTG provided webinars free of charge to members this past year. The following webinars were presented since January 2016: Nursing Collaboration to Improve the Management of a CardiOncology In-Patient Population, Karen Throndson, RN MN, and Darlene Grantham, RN MN Role of ASCT in Light Chain Amyloidosis in 2016, Donna Reece, BA, MD, FRCPC Bronchiolitis Obliterans Syndrome: Update of Diagnosis and Management, Guang-Shing Cheng, MD Unrelated Donor Selection Guidelines: HLA and Beyond, Stephen Spellman, MBS MSC s and GVHD: Where Are We Now and How Did We Get Here?, David Allan, MD, FRCPC Relapse of Hematologic Malignancies Post Hematopoietic Stem Cell Transplant, What is Next?, Haydar Frangoul, MD, MS The following webinars are planned for the remainder of the year. Should We Include Antithymocyte in Preparative Regimens for Unrelated Donor Transplant?, Irwin Walker, MBBS, FRACP, FRCPC CLL in the Novel Era, John Kuruvilla, MD, FRCPC 10
2015-2016 CBMTG ANNUAL REPORT National Registry The CBMTG has developed a comprehensive outcomes registry containing detailed clinical data on Canadians undergoing both autologous and allogeneic hematopoietic cell transplants from programs across Canada. We have data for over 18,000 patients dating back to 1990. The Registry is based in Winnipeg and is under the leadership of Dr. Kristjan Paulson. The Registry is an important research tool for CBMTG members. Some possible benefits of having country-wide data: 1. Transplant activity and practices across Canada can facilitate the design and conduct of clinical trials by CBMTG member centres. 2. Transplant outcomes reflecting Canadian clinical practice. 3. Practice patterns and outcomes can be used by health services researchers and programs to inform policy makers and payers about National standards of practice. The majority of the data will be collected through our partnership with CIBMTR. As part of FACT requirements, transplant programs collect Transplant Essential Data (TED) as defined by the CIBMTR. Through data sharing agreements, TED forms submitted to the CIBMTR can be forwarded to the CBMTG for inclusion in our National Registry. Canadian programs can also submit their data directly to the CBMTG Registry. PARTICIPATING CENTRES INCLUDE: British Columbia s Children s Hospital, Vancouver BC Vancouver General Hospital, Vancouver, BC Alberta Children s Hospital, Calgary AB University of Calgary Tom Baker Cancer Centre, Calgary AB CancerCare Manitoba, Winnipeg MB Health Science North, Sudbury ON Hamilton Health Sciences, Hamilton ON Kingston General Hospital, Kingston ON Princess Margaret Hospital, Toronto ON Hopital Maisonneuve-Rosemont, Montreal QC Montreal Children s Hospital, McGill University Health Centre, Montreal QC Centre Hospitalier Universitaire Sainte-Justine, Montreal QC CHA Enfant Jesus Hospital, Quebec City QC QE II Health Sciences Centre, Dalhousie Halifax NS Sick Kids Hospital, Toronto ON Ottawa Hospital, Ottawa, ON (in process) This past year, the registry has seen its first scientific project on conditioning regimens in autologous transplant for lymphoproliferative diseases. A second scientific project Transplant in Canada in the 21 st century is currently being worked on. Three new projects projects are under consideration this upcoming year. 11
DATA SUMMARY PATIENTS PERCENT TRANSPLANT TYPE Allogeneic 7693 16.3% Autologous 8794 52.9% DLI 126 0.7% GENDER Male 10740 57.3 Female 7939 42.3 GRAFT SOURCE Bone marrow 3264 18.7% Peripheral Blood 13731 78.6% Cord Blood 477 2.7% YEAR OF TRANSPLANT Before 2000 7339 39% 2000-2005 4260 22.7% 2006-7205 38.3% AGE Median 46.1 years < 18 4539 24.1% 18-40 4090 21.8% 40-60 7521 40% >60 2654 14.1% 12
2015-2016 CBMTG ANNUAL REPORT TRANSPLANTS BY DISEASE Disease Allogeneic Transplants Autologous Transplants Total Acute Myeloid Leukemia 2417 281 2726 Acute Lymphoblastic Leukemia 1124 18 1158 Other Acute Leukemia 364 6 384 Chronic Myeloid Leukemia 959 14 1023 Myeloproliferative/Myelodysplastic Diseases 821 1 830 Other Acute Leukemia 109 6 116 Non-Hodgkin Lymphoma 715 2454 3173 Hodgkin Lymphoma 70 1039 1109 Plasma Cell Disorder/Multiple Myeloma 197 3490 3689 Other Malignancy 26 885 912 Severe Aplastic Anemia 353 0 355 Red Cell Disorder 141 0 141 Immunodeficiency 167 0 167 Metabolic Disorder 68 0 68 Histiocyte Disorder 38 0 38 Autoimmune Disease 5 19 24 Research Queries A research proposal submitted to the Registry will be reviewed by the Scientific Director and Registry data manager to ensure that the request is feasible and the data requested is contained within the Registry, and the project will not require an excessive amount of work abstract by the data manager. As noted in the authorship proposal, if more than 20% of the patients in the data series are from one centre, then the proposal will be sent to the steering committee member for that centre for comment. For a more detailed report please connect with CBMTG head office at cbmtg@cbmtg.org. Data in the Registry spans the years of 1990 and 2014. At present, the data are incomplete and do not represent all transplant activity during this time period. 13
GVHD 2015 The 2015 GVHD symposium was held in Montreal in the fall of 2015. Once again we partnered with the Canadian Blood Services and Hema Quebec to put on an exciting scientific program. Presentations included: SHOULD WE INCLUDE ANTITHYMOCYTE GLOBULIN IN PREPARATIVE REGIMENS FOR UNRELATED DONOR TRANSPLANTS? Presented by Irwin Walker, MBBS, FRACP, FRCPC INTESTINAL BACTERIAL FLORA AND OUTCOMES AFTER ALLOGENEIC HCT Presented by Robert Jenq, MD BRONCHIOLITIS OBLITERANS SYNDROME: UPDATE ON DIAGNOSIS AND MANAGEMENT Presented by Guang-Shing Cheng, MD Conference Summary MSC S AND GVHD: WHERE ARE WE NOW AND HOW DID WE GET HERE? Presented by David Allan, MD, FRCPC LATE EFFECTS AFTER ALLOGENEIC SCT IN ADULTS Presented by Gérard Socie, MD, PhD ZERO-INTENSITY PREPARATION ALLOGENEIC TRANSPLANT USING DONOR T-RAPA CELLS Presented by Daniel H. Fowler, MD INDUCTION OF IMMUNE TOLERANCE IN PATIENTS WITH CHRONIC GVHD, Presented by Jerome Ritz, MD The 2016 conference was chaired by Dr. Raewyn Broady and Dr. Kirk Schultz. The conference was scheduled for April 27 to 30, 2016 at the Westin Bayshore, Vancouver BC. The committee consisted of: Raewyn Broady, MBChB, FRACP, FRCPC (Chair) Kirk Schultz, MD (Chair) Christopher Bredeson, MD, MSc Jean-Sebastien Delisle, MD, PhD Angela Hall, BSc Juliana Roden, MN, NP(P) Giovanna Cameron, MLT Maarten Egeler, MD, PhD Silvy Lachance, MD, FRCPC, CSPQ Jan Storek, MD, PhD Stephen Couban, MD, FRCPC Ronan Foley, MD, FRCPC Kirstjan Paulson, MD Dawn Warkentin, Pharm. D. Andrew Daly, MD, FRCPC Elie Haddad, MD, PhD Gizelle Popradi, MD, FRCPC Jennifer Wiernikowski, MN, NP-Adult, CON(C) 14
2015-2016 CBMTG ANNUAL REPORT Themed Meetings 2017 We are pleased to announce a series of meetings in 2017! These 1.5 day long meetings will include scientific sessions, keynote presentations, multidisciplinary and discipline specific session and corporate satellite symposia. We invite all BMT healthcare professionals to attend our meetings in 2017! MAY 2017 WINNIPEG, MANITOBA Led by Dr. David Szwajcer and Tracy Robinson, this meeting will include sessions focused Resilience and Empowerment. JUNE 2017 CALGARY, ALBERTA Led by Dr. Michelle Geddes, this meeting will focus on Innovation within the BMT field. SEPTEMBER 2017 ST. JOHN S, NEWFOUNDLAND Led by Dr. David Jones, this meeting will address mobilization considerations, both allo and auto, and long term follow up, complications and relapse. 2018 CBMTG Conference COMING SOON The 2018 CBMTG conference will be held in Ottawa, ON spring of 2018. 15
LEADERSHIP This upcoming fall the CBMTG will host a leadership session in conjuction with the CMA s Physician Leadership Institute. The goal will be to help develop the next set of leaders from the Canadian BMT community. CBMTG will invite a minimum of one representative from each Canadian BMT centre. The session will be held in Toronto. For more information, please connect with the CBMTG office. AWARDS The following awards were presented at the 2015 conference: Hans Messner Lectureship Award Paul Martin, MD Fred Saunders Lectureship Award Stephan Grupp, MD, PhD Till and McCulloch Lectureship Award Marcel van den Brink, MD, PhD Best Oral Abstract Denis-Claude Roy, MD Best Poster Award Josee Laganiere, PhD Best Poster award Laura Anne Habib, MD, CM Best Poster award Mia Golder, PhD Patty Bakkestad Legare Mike Halpenny, MLT Most Deserving Abstract Award Kevin Dawe, BSc The following awards were presented at the 2016 conference: Hans Messner Lectureship Award James Russell, MA, MB.BChir, FRCP Till and McCulloch Lectureship Award Connie Eaves, PhD, FRSC Best Oral Abstract Award Clinical: Trials/Observations Uday Deotare, MD Best Oral Abstract Award Clinical: Laboratory/Quality Mike Halpenny, MLT Best Oral Abstract Award Clinical: Pharmacy/Nursing/ Other Transplant Support Pamela Plantinga, BSc Best Oral Abstract Award Research: Basic/Translational Jacob Rozmus, MD Best Overall Oral Abstract Award Kristjan Paulson, MD, FRCPC Best Poster Abstract Award Mileidys Alvarez, BSc (Hons) Best Poster Abstract Presentation Award Natasha Kekre, MD, MPH, FRCPC Patty Bakkestad Legare Award Mike Halpenny, MLT and Mileidys Alvarez, BSc (Hons) 16
2015-2016 CBMTG ANNUAL REPORT ASSOCIATION SPONSORS Conference sponsors Platinum Sponsor Gold Sponsors Silver Sponsors Conference Supporters Symposia Supporters Conference Contributors Lab Session Sponsor Exhibitors Amgen Inc. Biosafe America, Inc. Celgene, Inc. Digi-Trax Corporation Fresenius Kabi Canada Ltd. Janssen, Inc. Jazz Pharmaceuticals Lundbeck Canada Inc. Macopharma Canada Inc. Merck Canada Novartis Pharmaceuticals Canada, Inc. Otsuka Canada Pharmaceutical Inc. Pfizer Canada Inc. Sanofi Genzyme Seattle Genetics, Inc. StemSoft Software Inc. 17
GVHD Symposia Sponsors The 2015 sponsor of the GVHD Symposium was Sanofi. The 2016 sponsors of the GVHD Symposium is Sanofi Genzyme and Jazz Pharmaceuticals. National Registry Sponsor CBMTG s Platinum Sponsor for the Registry in 2016 is Astellas. 18
2015-2016 CBMTG ANNUAL REPORT AUDITED FINANCIAL STATEMENTS 19
20
21
22
23
24
25
26
27
28
29
30
2015-2016 CBMTG ANNUAL REPORT 31
CBMTG HEAD OFFICE 570 West 7th Avenue, Suite 400 Vancouver, BC V5Z 1B3 T: 604-874-4944 F: 604-874-4378 E: cbmtg@cbmtg.org W: www.cbmtg.org